Clin Pharmacol Biopharm 2016, 5:4(Suppl)
http://dx.doi.org/10.4172/2167-065X.C1.023

4th International Pharma & Clinical Pharmacy Congress

Molecular mechanism investigation of a novel Ruthenium (II) complex inhibits proliferation of human esophageal squamous cell carcinoma

Jiangsu Institute of Nuclear Medicine, China

High toxicity acquired resistance and serious side e ets, prompting the search for novel compounds for cancer treatment. Retly, a Ruthenium (II) complex [Ru (p-cymene)(L)Cl2] (L = 1,3-bis(4-(tert-butyl)benzyl)-1H-imidazol-3-ium chride) , which name-4, has benthesizend characterize. e purpose of this study was to investte the e ets of L-4 ainst human esophaeaquamous carcinoma (ESCC) cele EC109. Di e(a)9ins s9 (os)-80.6c/dm Tie3 (a)9 (r [R)2m) cea +ts eets